Loading
ClearPoint Neuro, Inc. Stock: price and insider trades · United States
ClearPoint Neuro, Inc.: what insiders have been doing
ClearPoint Neuro, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for ClearPoint Neuro, Inc. logged 56 filings by 13 insiders.
Only sales appear on the open market, 9 sales in all totalling €837k, filed by 4 insiders. No amount is published for 3 filings, which the totals therefore leave out. The largest single trade was a sale of €277k by Burnett Joseph, published on 13 January 2026.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Compared with its exchange (5,458 companies, median 22 filings), a count of 56 filings is above the norm. Over the whole record (from 2016), the tally stands at no purchases and 16 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 37.0 m USD and net income at -25.5 m USD.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
240
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€2M
16 ops. · all time
Who traded when
BuySaleJoseph Burnett8 sales
Lynnette C. Fallon2 sales
Timothy T. Richards2 sales
Matthew B. Klein1 sale
Analyst consensus: bullish or bearish?
Analysts rate ClearPoint Neuro, Inc. Strong Buy (bullish), based on 2 analysts. Average price target: US$23.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,250 of 24,161 companies
24.3
score / 100
Value21
Quality27
FCF yld-5.2%
Earn yld-5.5%
EV/EBITDA·
ROE-227%
Gross mgn61%
Net mgn-69%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$15.31
Analyst consensus
2 analystsStrong buy
US$22.00Target US$23.50(+53%)US$25.00
Income statement
RevenueUS$37M
Gross profitUS$22.7M61% margin
EBITDA-US$20.9M-56% margin
Net income-US$25.5M-81.8% margin
Valuation
PER (forward)-12.8x
P/Book43.4x
Beta1.27
Balance sheet & cash
Market capUS$467M
Total debtUS$58.2M
Free Cash Flow-US$24.4M
Debt / Equity593%
Profitability & ownership
ROE-226.5%
ROA-24.4%
% insiders5.5%
% institutions52.5%
Last declaration on 2 October 2026
Declarations240 total
319 shares@ US$12.210.0008% mcap0.9% of flowCommon StockSEC:0001193125-26-412434:0
993 shares@ US$12.210.0026% mcap5.0% of flowCommon StockSEC:0001193125-26-412424:0
12,517 shares@ US$3.470.0094% mcap2.4% of flowCommon StockSEC:0001193125-26-382208:0
662 shares@ US$17.840.0026% mcap5.1% of flowCommon StockSEC:0001193125-26-296615:0
222 shares@ US$17.840.0009% mcap0.9% of flowCommon StockSEC:0001193125-26-296614:0
1,361 sharesCommon StockSEC:0001193125-26-294474:0
20,000 sharesCommon StockSEC:0001193125-26-292932:0
20,000 sharesCommon StockSEC:0001193125-26-292932:1
20,000 shares@ US$18.480.081% mcap100.0% of flowCommonSEC144:0001950047-26-006598
60,000 sharesCommon StockSEC:0001193125-26-277503:1
60,000 sharesCommon StockSEC:0001193125-26-277503:0
1,843 sharesCommon StockSEC:0001193125-26-277503:2
60,000 shares@ US$13.340.15% mcap100.0% of flowCommonSEC144:0001950047-26-006271
1,843 shares@ US$13.340.0046% mcap100.0% of flowCommonSEC144:0001950047-26-006274
500 shares@ US$10.000.0011% mcap1.2% of flowCommon StockSEC:0001193125-26-261835:0
376 shares@ US$13.300.0011% mcap1.2% of flowCommon StockSEC:0001193125-26-261835:1
5,415 shares@ US$12.170.014% mcap15.3% of flowCommon StockSEC:0001193125-26-253602:0
16,000 shares@ US$11.590.039% mcap100.0% of flowCommon StockSEC:0001193125-26-239431:0
5,091 shares@ US$11.140.012% mcap33.0% of flowCommon StockSEC:0001193125-26-234575:1
12,417 sharesCommon StockSEC:0001193125-26-234577:0
12,417 sharesCommon StockSEC:0001193125-26-234562:0
12,417 sharesCommon StockSEC:0001193125-26-234565:0
12,417 sharesCommon StockSEC:0001193125-26-234569:0
12,417 sharesCommon StockSEC:0001193125-26-234570:0
12,417 sharesCommon StockSEC:0001193125-26-234574:0
25 of 240 declarations
About ClearPoint Neuro, Inc.
ClearPoint Neuro, Inc. (ticker: CLPT) is a U.S.-listed company traded on the NASDAQ, focused on precision neurosurgery and targeted delivery solutions for the brain and spine. For French, Belgian, and Swiss investors, it fits the profile of a niche medtech company operating at the intersection of medical devices, cell therapy, and gene therapy enablement. The company is headquartered in Solana Beach, California, and also maintains manufacturing capabilities in Carlsbad, giving it a concentrated operational footprint on the west coast of the United States. ([clearpointneuro.com](https://www.clearpointneuro.com/about/?utm_source=openai))
ClearPoint Neuro was built around a precision navigation platform for intracranial procedures. Its core value proposition is real-time, image-guided hardware and software that allows neurosurgeons to make intraprocedural adjustments with a high degree of accuracy. That is strategically important because it gives the company a more defensible position than a commoditized medical-device supplier. ClearPoint emphasizes its technology depth, clinical utility, patent portfolio, and expanding adoption across specialized neurosurgical workflows. ([clearpointneuro.com](https://www.clearpointneuro.com/about/?utm_source=openai))
Read moreShow less
From a business-segment perspective, CLPT is not a single-product story. Its platform is used in deep brain stimulation, laser ablation, biopsy, neuro-aspiration, and the delivery of drugs, biologics, and gene therapies to the brain. The company describes itself as a “device, cell, and gene therapy-enabling company,” which positions it more as an infrastructure provider for advanced neuroscience treatments than as a traditional instrument maker. This model can support a revenue mix that includes systems, disposables, and a growing partner ecosystem in biopharma. ([clearpointneuro.com](https://www.clearpointneuro.com/about/?utm_source=openai))
In competitive terms, ClearPoint operates in a specialized market where clinical credibility, precision, and workflow integration matter more than scale alone. Its differentiation comes from neurosurgical navigation expertise and from its ability to support cell and gene therapy programs with pharmaceutical partners. The company stated that it has more than 60 active biopharma partners and is supporting more than 25 global clinical trials, reinforcing its role as a platform enabling CNS-focused innovation. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1285550/000119312526110780/clpt-ex99_1.htm?utm_source=openai))
Recent developments have included the company’s first-quarter 2026 results released on May 13, 2026, along with ongoing execution on its expanded commercial platform. ClearPoint has also highlighted the acquisition and commercialization of a neurocritical care product line from IRRAS, as well as software innovation, including FDA-cleared updates to its 2.2 software version. For investors, this points to a company that is evolving from a focused neuromodulation/navigation specialist into a broader neuroscience platform with multiple growth vectors, while still depending on clinical adoption and partner momentum. ([ir.clearpointneuro.com](https://ir.clearpointneuro.com/news-events/press-releases?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
